Compare Gilead Sciences, Inc. (GILD) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Energy Select Sector SPDR Fund — how do they compare? Gilead Sciences, Inc. trades at $136.73 (market cap $168.35B), while Energy Select Sector SPDR Fund trades at $60.87. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Energy Select Sector SPDR Fund pays none, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | XLE | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | — |
52-Week High | $155.80 | $62.57 |
52-Week Low | $110.56 | $42.33 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
XLE trades at $60.47, up 0.47% with a bullish technical signal from moving averages. The ETF has rallied 40.52% over the past year, driven by strong oil prices and geopolitical tensions in the Middle East. Recent earnings from major holdings like ExxonMobil and Chevron showed profit surges, supporting the sector's momentum. Technical indicators show support at $59 and resistance at $61, with RSI readings in neutral territory suggesting room for further movement.
Outlook remains positive but faces geopolitical risks. The energy sector benefits from elevated oil prices and strong earnings, though concentration in a few large stocks and sensitivity to Middle East tensions present volatility. Analyst sentiment is mixed with some calling the entry point less attractive after the rally, while others see continued upside potential from supply disruptions and AI infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
